Evidaxia

JCA Pulse › JCA report published

JCA report published

Tovorafenib (Ojemda): EU joint clinical assessment

Paediatric low-grade glioma with a BRAF fusion, rearrangement or V600 mutation, after at least one prior systemic therapy

  1. Regulatory review
  2. CHMP opinion
  3. EU authorised
  4. JCA report published

Overview

Company
Ipsen
Therapy area
Solid tumours · Paediatric brain
Indication
Paediatric low-grade glioma with a BRAF fusion, rearrangement or V600 mutation, after at least one prior systemic therapy
Product type
Orphan designation
EC marketing authorisation
20 Apr 2026
JCA report published
9 Jun 2026
JCA assessor
NCPE, Ireland
Co-assessor
IQWiG, Germany
Pivotal evidence
FIREFLY-1 (single-arm phase 2, pivotal cohort n=77)
01

Scope

From the published report

The JCA report set out 8 PICOs across 3 populations.

Three populations: the full indication; BRAF V600E mutation in patients over 1 year; and BRAF fusion, rearrangement or V600 non-E mutation. Comparators ranged from dabrafenib + trametinib, trametinib, carboplatin + vincristine and vinblastine to individualised treatment.

JCA report on the European Commission website

02

Evidence

How the evidence covered the scope

Comparative evidence informed 1 of the 8 PICOs. Pro breaks down how the evidence covered each one, and what it means for later submissions.

Included in Pro
03

Countries

National translator and outlook

Ireland and Germany lead the joint assessment. Pro explains what the JCA means for the national route in each of 31 markets, with 4 national records already in place.

See JCA Pulse ProIncluded in Pro

Next milestones

  • Early Nov 2026G-BA resolution scheduled · Germany · source

Sources

Last checked 5 November 2026. Compiled from public sources; check them for the latest position. Forecasts are Evidaxia’s independent view, not official assessments.

From Evidaxia

Also in Solid tumours